Hemostemix Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was CAD 5.24 million compared to CAD 6.29 million a year ago. Basic loss per share from continuing operations was CAD 0.075 compared to CAD 0.109 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.04 CAD | -11.11% |
|
-27.27% | -42.86% |
11/06 | Hemostemix Announces Strategic Manufacturing Partnership with Cytoimmune Therapuetics | CI |
03/06 | Hemostemix Inc. announced that it expects to receive CAD 2 million in funding | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-42.86% | 25.52L | |
+16.45% | 12TCr | |
+21.96% | 12TCr | |
+25.50% | 2.7TCr | |
-20.05% | 2.04TCr | |
-16.28% | 1.59TCr | |
-15.89% | 1.64TCr | |
-44.35% | 1.56TCr | |
+63.91% | 1.49TCr | |
+2.52% | 1.36TCr |
- Stock Market
- Equities
- HEM Stock
- News Hemostemix Inc.
- Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2022